PTD4-apoptin protein therapy inhibits tumor growth in vivo

✍ Scribed by Jun Sun; Ying Yan; Xiao-Ting Wang; Xiao-Wen Liu; Dong-Jun Peng; Min Wang; Jun Tian; Yi-Qiang Zong; Ying-Hui Zhang; Mathieu H.M. Noteborn; Shen Qu

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: French
• Weight: 933 KB
• Volume: 124
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.24279

✦ Synopsis

Abstract

Apoptin protein harbors tumor‐selective cell death activity, which makes it a potential anticancer therapy candidate. This study reports an apoptin therapy approach based on protein transduction domain 4 (PTD4)‐mediated transduction of recombinant apoptin protein. In vitro, the PTD4‐apoptin fusion protein is located in the nucleus and induces cell death in, e.g., human hepatocarcinoma HepG2 cells. In normal human L‐02 hepatocytes, PTD4‐apoptin protein retained mainly cytoplasmic and did not induce detectable levels of cell death, illustrating that the PTD4 domain does not affect apoptin's tumor‐selective characteristics. In vivo, liver, cervix and gastric carcinoma xenografts treated with PTD4‐apoptin protein for 6 days via the tumor epidermis exhibited a significant tumor growth inhibition because of apoptin‐mediated cell death. In addition, treatment of human hepatocarcinoma xenografts during 3 weeks showed that PTD4‐apoptin protein has significant anticancer activity, whereas control treatment with PTD4‐enhanced green fluorescence protein or saline did not. Cell death and disruption of the tumor integrity were apparent in the PTD4‐apoptin transduced xenografted tumors. As important, although PTD4‐apoptin protein could be detected in the epidermal tissue covering the subcutaneous tumor tissue and in several organs, such as liver and brain, of the treated mice, no tissue disruption or signs of cell death could be detected. Our in vivo data reveal that apoptin protein delivery constitutes a novel powerful and safe anticancer therapy. © 2009 UICC